Phyton Biotech Expands Leadership Team with the Appointment of a New Vice President of Business Development

Stephen Ball Joins the Specialty Fermentation Solutions Biotech Company as VP of Business Development with a Focus on Strategic Growth and Expansion into New Industries

Delta, Canada, January 4, 2022 — Phyton Biotech, Ltd., a global leader in specialty fermentation solutions for naturally derived compounds and the largest global supplier of Paclitaxel and Docetaxel via Plant Cell Fermentation® (PCF), is pleased to announce the appointment of Stephen Ball as the Company’s new VP of Business Development, Strategic Growth.

Ball joins Phyton Biotech’s management team, and will be working directly with Phyton’s President Colin Marr, and the Company’s Board of Directors. In addition to liaising with company stakeholders, partners and customers, Ball’s area of focus will be identifying opportunities within the Company and industry for strategic growth. He will be responsible for the expansion of Phyton’s business portfolio, which includes seeking new opportunities for manufacturing through fermentation in pharmaceuticals, nutraceuticals, cosmetics and food ingredients.

“Phyton is rooted in creativity, innovation, and supporting the development of safe and beneficial products using our technology through specialty fermentation for naturally derived compounds,” said Colin Marr, President of Phyton Biotech. “Stephen’s experience in scaling businesses and the pharmaceutical industry will make him an incredible asset to the Phyton team and I look forward to working with him.”

Ball has worked in the biotechnology industry for more than 15 years. He previously worked for Natural Products Canada (NPC) as a Regional Director. In this role, he supported the startup ecosystem through evaluating early-stage technologies, recommending direct investment opportunities, business plan development, and collaborating with funding agencies. Prior to this, Ball spent time at BioVectra Inc., where he rose through the ranks from Custom Project Manager to Director of Sales & Marketing. During his tenure at BioVectra, Ball managed strategic partnerships and competitive intelligence to ensure continued growth of the business.


Phyton Biotech, a wholly-owned subsidiary of DFB Pharmaceuticals, is a global leader in Plant Cell Fermentation (PCF®) Technology, offering comprehensive services for the development and commercialization of plant-based molecules, extracts and recombinant products, serving the pharmaceutical, Chinese Traditional Medicine, cosmetic, agricultural and food ingredient industries. Using PCF®, Phyton Biotech offers a time, risk and cost-balanced path to commercially viable production processes, overcoming limitations often experienced with traditional plant extraction and chemical synthesis. As a biotechnology leader with certified GMP facilities in Germany and Canada, Phyton Biotech has a successful track record of developing and implementing innovative specialty fermentation solutions for naturally derived compounds for clients around the world. The company is now the world’s largest producer of paclitaxel and docetaxel via PCF®, with the capacity to meet more than one-third of the global demand for these critical active pharmaceutical ingredients. For more information, please visit

For further information, please contact:

Media Relations Contact:

Julia Smith, Finch Media

Phone: +1604.803.0897
Email: [email protected]